Skip to main content

Access to Essential Cancer Medicines

For UICC members only badgeAbout UICC's self-guided courses

  • This course was originally designed as a Master course. It was delivered from July to October 2020.
  • It is now open to all UICC members registered on the eLearning platform.
  • You may complete all items in this course or complete only the items that are of interest to you. If you complete all course items you will receive a certificate of completion.
  • This course has been accredited by the Accreditation Council of Oncology in Europe (ACOE) and its completion gives 4 European CME Credits
  • This course is self-paced. The required time to complete this course is approximately┬á5 hours.
  • To access the course you must sign in to the eLearning platform. If you are not registered and work for a UICC member organisation, you can sign up here.
Course overview
The purpose of this course is to review the landscape and challenges in access of essential cancer medicines, especially in low- and middle-income countries, and delve into a methodology for evaluating medicine availability and approaches to mitigating drug stock-outs. The course will take a holistic evaluation of cancer medicine access, including factors unrelated to price, and will focus on potential solutions to mitigating the various challenges around access.

Learning Objectives
At the end of this course, participants will be able to:
  1. Describe the current landscape of essential cancer medicine access and identify challenges related to cancer medicine access globally, with a focus on developing countries
  2. Examine measures and definitions of cancer medicines access and its impact on clinical health outcomes
  3. Report on potential solutions to mitigating cancer therapy access
  4. Provide a holistic evaluation of cancer medicine access, including factors unrelated to drug price, by examination of external health system and patient factors related to access
Target Audience
The following audience would particularly benefit from this course:
  • Providers who prescribe and administer chemotherapy
  • Agencies involved in formulation, procurement and supply of national essential medicines for cancer treatment
  • Advocates promoting better access, with a focus on low and middle income countries